Singapore, Aug. 26 -- Haisco Pharmaceutical Group Co. has entered into an exclusive licensing agreement with Sentivera, a new US venture founded by Population Health Partners (PHP) and ARCH Venture Partners, to grant Sentivera the rights to develop, manufacture, and commercialise its independently developed one pre-clinical innovative drug globally, excluding Greater China.

The total deal value reaches over $1.5 billion, including an upfront payment and equity consideration in the new venture totaling $75.89 million, up to $1.46 billion in development, regulatory, and commercial milestone payments, and mid-single digits to low double digit tiered royalties on post-launch net sales.

As a core immunology asset of Haisco, this asset inhibi...